Eunha Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eunha Lee has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Han Young Chung
College of Pharmacy, Chungnam National University, Daejeon 34134, Republic of Korea
1 shared publication - Hanjin Park
College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 15588, Republic of Korea
1 shared publication - Jun Chang
Graduate School of Pharmaceutical Sciences, Ewha Womans University, Republic of Korea
1 shared publication - Ok-Nam Bae
College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 15588, Republic of Korea
1 shared publication - Sungbin Choi
College of Pharmacy Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 15588, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 29 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11606
Red Blood Cell-Associated Features of Adenoviral Vector-Linked Venous Thrombosis
Adenoviral vector vaccines were pivotal for COVID-19 control, but postmarketing safety surveillance has identified venous-predominant thrombotic risks not fully explained by platelet-centric mechanisms. We tested an RBC-associated hypothesis using an Ad5 vector-rAd/HA(PR8) rat model within a predefined sub-hemolytic window (8–109 OPU/Rat). In vivo, an inferior vena cava thrombosis model showed a pronounced, dose-responsive rise in thrombus burden, consistent with increased thrombogenic potential. Together, these integrated data provide experimental evidence consistent with RBC involvement under adenoviral exposure, supporting a biologically plausible link to the venous-predominant epidemiology observed during the COVID-19 vaccination era. Reported clinical adenoviral vaccine doses are of the same order of magnitude as the exposures tested here, supporting translational relevance while not implying inter-species or product equivalence. Incorporating RBC-focused endpoints, including PS exposure, morphology indices, microvesicle counts, and thrombin generation, into preclinical and early clinical assessments may enhance safety evaluation and inform vector design to mitigate venous thrombotic risk.
- 29 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11606
Open AccessRed Blood Cell-Associated Features of Adenoviral Vector-Linked Venous Thrombosis
Adenoviral vector vaccines were pivotal for COVID-19 control, but postmarketing safety surveillance has identified venous-predominant thrombotic risks not fully explained by platelet-centric mechanisms. We tested an RBC-associated hypothesis using an Ad5 vector-rAd/HA(PR8) rat model within a predefined sub-hemolytic window (8–109 OPU/Rat). In vivo, an inferior vena cava thrombosis model showed a pronounced, dose-responsive rise in thrombus burden, consistent with increased thrombogenic potential. Together, these integrated data provide experimental evidence consistent with RBC involvement under adenoviral exposure, supporting a biologically plausible link to the venous-predominant epidemiology observed during the COVID-19 vaccination era. Reported clinical adenoviral vaccine doses are of the same order of magnitude as the exposures tested here, supporting translational relevance while not implying inter-species or product equivalence. Incorporating RBC-focused endpoints, including PS exposure, morphology indices, microvesicle counts, and thrombin generation, into preclinical and early clinical assessments may enhance safety evaluation and inform vector design to mitigate venous thrombotic risk.